{{Rsnum
|rsid=2011077
|Gene=FGFR4
|Chromosome=5
|position=177094455
|Orientation=plus
|GMAF=0.2493
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=FGFR4
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 3.5 | 31.9 | 64.6
| HCB | 22.6 | 59.1 | 18.2
| JPT | 32.7 | 47.8 | 19.5
| YRI | 0.0 | 4.8 | 95.2
| ASW | 0.0 | 7.0 | 93.0
| CHB | 22.6 | 59.1 | 18.2
| CHD | 28.0 | 48.6 | 23.4
| GIH | 3.0 | 41.6 | 55.4
| LWK | 0.0 | 5.5 | 94.5
| MEX | 13.8 | 32.8 | 53.4
| MKK | 0.0 | 3.2 | 96.8
| TSI | 2.0 | 25.5 | 72.5
| HapMapRevision=28
}}
A study of ~500 Japanese [[prostate cancer]] patients found that individuals with a [[rs2011077]](G;G) genotype had a 6.2- and 3-fold increased risk of [[prostate cancer]] and benign prostate hyperplasia (BPH), and a 5.5-fold increased risk of metastatic prostate cancer, compared to the (A;A) genotype.{{PMID|18756523}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}